LFG
CMPX icon

Larson Financial Group’s Compass Therapeutics CMPX Stock Holding History

Larson Financial Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122 Buy
+23
New +$133 ﹤0.01% 3504

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Larson Financial Group's CMPX Position: Q1 2026 in Review

Larson Financial Group opened a new position in Compass Therapeutics (CMPX) in Q1 2026: 23 shares worth $122. The stake represents ﹤0.01% of the portfolio and ranks #3504 among its holdings.

201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Larson Financial Group held 23 shares of Compass Therapeutics worth $122 as of Q1 2026.
  • Compass Therapeutics was a new Larson Financial Group position in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3504 holding.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.